Glenmark Pharmaceuticals stock fell 2.36% on October 5

Published on 10/05/2026 at 10:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Glenmark Pharmaceuticals stock traded at INR 2,276 on the NSE on October 5, below its INR 2,537.60 52-week high. Q1 FY27 revenue reached INR 40,184.83 million.

Glenmark, INE935A01035, Illustration mit AI erstellt.

Glenmark Pharmaceuticals stock (ISIN INE935A01035) was last at INR 2,276 on the NSE on October 5, 2026, down 2.36 percent from the previous close. The market is weighing a strong Q1 FY27 earnings comparison against a share price that remains INR 261.60 below its 52-week high of INR 2,537.60.

Q1 revenue reaches INR 40.18 billion

According to Investing.com, Glenmark reported Q1 FY27 revenue of INR 40,184.83 million and net income of INR 4,829.24 million after its July 31, 2026 release. Diluted EPS was INR 17.11 against an EPS forecast of INR 17.10, while revenue exceeded the forecast of INR 39,490 million.

The sequential comparison was also positive in the figures published by Investing.com: revenue rose from INR 38,307.04 million in the prior quarter to INR 40,184.83 million, while net income increased from INR 3,014.14 million to INR 4,829.24 million. The improvement gives the earnings narrative more weight than a single quarter's headline beat.

FDA inspection adds operating context

Glenmark's regulatory backdrop also changed on September 23, 2026. Moneycontrol reported that the company received an Establishment Inspection Report for its Goa facility with a Voluntary Action Indicated classification from the U.S. FDA.

That regulatory update matters because Glenmark's formulations business spans respiratory, dermatology, oncology and other therapeutic areas. The Q1 numbers show the earnings base, while the inspection outcome remains a separate operational marker for the company's U.S. business.

Consensus target stays above INR 2,276

The published analyst consensus is Buy from 12 analysts, with 10 Buy ratings, 2 Holds and 0 Sells, according to Investing.com. The average 12-month target is INR 2,497.73, with a high of INR 2,750 and a low of INR 2,100; the average target lies 9.7 percent above the October 5 price.

For investors, the central tension is visible in the numbers: quarterly net income rose to INR 4,829.24 million from INR 3,014.14 million sequentially, while the stock traded 10.3 percent below its 52-week high. The next market test is whether subsequent results can extend the Q1 improvement.

Glenmark stock trades below yearly high

Glenmark Pharmaceuticals stock was last at INR 2,276 on the NSE at 2:26 p.m. IST on October 5, 2026. The session range was INR 2,273.50 to INR 2,340.50, with volume of 390,260 shares.